Madsbad S - Search Results

1

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.

Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T. Knop FK, et al. Among authors: madsbad s. Diabetologia. 2007 Apr;50(4):797-805. doi: 10.1007/s00125-006-0566-z. Epub 2007 Jan 16. Diabetologia. 2007. PMID: 17225124

2

On the effects of human galanin in man.

Holst JJ, Bersani M, Hvidberg A, Knigge U, Christiansen E, Madsbad S, Harling H, Kofod H. Holst JJ, et al. Among authors: madsbad s. Diabetologia. 1993 Jul;36(7):653-7. doi: 10.1007/BF00404076. Diabetologia. 1993. PMID: 7689499

3

The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.

Toft-Nielson M, Madsbad S, Holst JJ. Toft-Nielson M, et al. Among authors: madsbad s. Diabetes. 1996 May;45(5):552-6. doi: 10.2337/diab.45.5.552. Diabetes. 1996. PMID: 8621002

4

Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.

Toft-Nielsen M, Madsbad S, Holst JJ. Toft-Nielsen M, et al. Among authors: madsbad s. Diabetologia. 1998 Oct;41(10):1180-6. doi: 10.1007/s001250051049. Diabetologia. 1998. PMID: 9794105

5

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Vilsbøll T, et al. Among authors: madsbad s. Diabetes Care. 2000 Jun;23(6):807-12. doi: 10.2337/diacare.23.6.807. Diabetes Care. 2000. PMID: 10841001

6

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Vilsbøll T, et al. Among authors: madsbad s. Diabetes. 2001 Mar;50(3):609-13. doi: 10.2337/diabetes.50.3.609. Diabetes. 2001. PMID: 11246881

7

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Vilsbøll T, et al. Among authors: madsbad s. Diabet Med. 2001 Feb;18(2):144-9. doi: 10.1046/j.1464-5491.2001.00424.x. Diabet Med. 2001. PMID: 11251679

8

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.

Toft-Nielsen MB, Madsbad S, Holst JJ. Toft-Nielsen MB, et al. Among authors: madsbad s. J Clin Endocrinol Metab. 2001 Aug;86(8):3853-60. doi: 10.1210/jcem.86.8.7743. J Clin Endocrinol Metab. 2001. PMID: 11502823

9

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Vilsbøll T, et al. Among authors: madsbad s. Diabetologia. 2002 Aug;45(8):1111-9. doi: 10.1007/s00125-002-0878-6. Epub 2002 Jul 4. Diabetologia. 2002. PMID: 12189441

10

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ. Vilsbøll T, et al. Among authors: madsbad s. J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13. doi: 10.1210/jc.2002-021873. J Clin Endocrinol Metab. 2003. PMID: 12788877

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

604 results

Search Page

Filters